We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+25.03%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.13B
AUM Growth
-$243M
Cap. Flow
-$918M
Cap. Flow %
-29.36%
Top 10 Hldgs %
37.92%
Holding
89
New
20
Increased
16
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$55.4M
2
KOD icon
Kodiak Sciences
KOD
+$42.4M
3
BTSG icon
BrightSpring Health Services
BTSG
+$40.1M
4
CLDX icon
Celldex Therapeutics
CLDX
+$33.4M
5
ILMN icon
Illumina
ILMN
+$31.7M

Top Sells

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$74.8M
2
KRYS icon
Krystal Biotech
KRYS
+$67M
3
CGON icon
CG Oncology
CGON
+$58.5M
4
APGE icon
Apogee Therapeutics
APGE
+$54.4M
5
DHR icon
Danaher
DHR
+$42M

Sector Composition

Rank Sector Weight
1 Healthcare 83.49%
2 Miscellaneous 16.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZURA icon
51
Zura Bio
ZURA
$548M
$16.7M 0.53%
3,180,389
+707,583
+29% +$2.8M
CMPX icon
52
Compass Therapeutics
CMPX
$432M
$15M 0.48%
+2,786,778
New +$12.9M
GLUE icon
53
Monte Rosa Therapeutics
GLUE
$1.14B
$14.9M 0.48%
+948,316
New +$12.8M
HROW icon
54
Harrow
HROW
$1.4B
$14.5M 0.46%
295,291
-47,100
-14% -$1.98M
XFOR icon
55
X4 Pharmaceuticals
XFOR
$401M
$13.5M 0.43%
+3,368,904
New +$12.2M
RGEN icon
56
Repligen
RGEN
$9.95B
$13.4M 0.43%
81,790
-113,866
-58% -$17.8M
ICLR icon
57
Icon
ICLR
$13.1B
$13.4M 0.43%
+73,370
New +$13.1M
KNSA icon
58
Kiniksa Pharmaceuticals
KNSA
$6.09B
$12.9M 0.41%
313,823
-329,357
-51% -$13.2M
GRAL
59
GRAIL Inc
GRAL
$3.57B
$12.2M 0.39%
+142,755
New +$12.3M
SRZN icon
60
Surrozen
SRZN
$264M
$10.6M 0.34%
470,000
+330,000
+236% +$5.34M
RLMD icon
61
Relmada Therapeutics
RLMD
$462M
$7.64M 0.24%
+1,582,257
New +$5.3M
XNCR icon
62
Xencor
XNCR
$1.94B
$7.03M 0.22%
459,166
-787,114
-63% -$11.8M
CSTL icon
63
Castle Biosciences
CSTL
$1.02B
$6.89M 0.22%
177,183
-645,552
-78% -$20.8M
ADPT icon
64
Adaptive Biotechnologies
ADPT
$4.02B
$5.07M 0.16%
311,991
-424,023
-58% -$6.92M
BLLN
65
BillionToOne Inc
BLLN
$4.4B
$4.09M 0.13%
+50,000
New +$5.07M
ORKA
66
Oruka Therapeutics
ORKA
$6.03B
$2.57M 0.08%
84,795
-1,297,555
-94% -$36.2M
KPTI icon
67
Karyopharm Therapeutics
KPTI
$42.4M
$2.23M 0.07%
+303,370
New +$1.86M
LUNG icon
68
Pulmonx
LUNG
$102M
$1.66M 0.05%
752,541
– –
AKRO
69
DELISTED
Akero Therapeutics
AKRO
– –
-475,400
Closed -$22.6M
AMLX icon
70
Amylyx Pharmaceuticals
AMLX
$3.87B
– –
-612,841
Closed -$8.33M
ATEC icon
71
Alphatec Holdings
ATEC
$1.46B
– –
-1,514,604
Closed -$22M
DAWN
72
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-2,181,598
Closed -$15.4M
EHC icon
73
Encompass Health
EHC
$11.9B
– –
-113,335
Closed -$14.4M
EXAS
74
DELISTED
Exact Sciences
EXAS
– –
-414,600
Closed -$22.7M
GMED icon
75
Globus Medical
GMED
$11.1B
– –
-498,000
Closed -$28.5M
1 2
3
4

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q4 2025 Portfolio in Review

As of Q4 2025, Braidwell held 89 positions worth $3.13B, down 7.2% from $3.37B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Braidwell withdrew a net $918M in Q4 2025, closing 16 positions and reducing 29 holdings. Its most notable exit was Globus Medical, an estimated $28.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 73% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in Centessa Pharmaceuticals worth $54.7M.

  • Braidwell's largest Q4 2025 buy was Centessa Pharmaceuticals: 2,188,320 shares worth $54.7M.
  • Braidwell added most to Celldex Therapeutics in Q4 2025, an estimated $33.4M increase.
  • Braidwell's biggest Q4 2025 reduction was Xenon Pharmaceuticals, cutting an estimated $74.8M.
  • Braidwell fully exited Globus Medical in Q4 2025, selling an estimated $28.5M.
  • Braidwell's ten largest holdings make up 38% of its $3.13B portfolio in Q4 2025.
  • Braidwell opened 20 new positions and closed 16 in Q4 2025.
  • Braidwell's portfolio value fell 7.2% quarter-over-quarter to $3.13B.

Based on Braidwell's 13F filing for Q4 2025, filed 17 Feb 2026.